Skip to main content
. Author manuscript; available in PMC: 2016 Jan 1.
Published in final edited form as: Cancer Prev Res (Phila). 2014 Nov 3;8(1):27–36. doi: 10.1158/1940-6207.CAPR-14-0193

Figure 4. Effects of carvedilol and atenolol on EGF-induced AP-1 transactivation.

Figure 4

HEK-293 expressing an AP-1 luciferase reporter and renilla control were treated with vehicle control, EGF (10 ng/mL), EGF plus β-blockers carvedilol (A) or atenolol (B) for 24 h; data shown as means ± SE. Groups with different Greek letters are statistically different (p < 0.05) as determined by ANOVA with Tukey-Kramer post hoc test; n = 5.